

## Advanced medical research technology and organoid-based drug screening for new drug development and personalized precision medicine

### MBD Overview

MBD (Medical & Bio Decision) is focused on technologies supporting new drug development and personalized precision medicine by the development of organoid-based drug screening and utilizing of 3D cell culture. MBD has developed a unique, fully automated HTS (high-throughput screening) Platform for hospitals and advanced medical clinics for identifying the most effective treatment to each individual. The process results in predicting the most effective treatment both fast and with high accuracy. The company has conducted clinical trials on many cancer types (lung, ovarian, stomach, head/neck cancer, esophageal cancers) and will soon expand the technology to apply also to prostate, colo, and pancreatic cancers.

### International Recognitions

- Presidential Commendation (2025): Awarded for Merit in Science and Technology on Science Day, recognizing our contribution to national technological innovation.
- 2025 4IR Awards: Winner of the Grand Prize in the Bio-health category, acknowledging our leadership in the 4th Industrial Revolution technologies.
- Certificate of Korea's National Institute of Medical Device Safety Information

### Business Model

Revenue Model	Platform and Equipment Sales Organoid-based Research Service Patient-Specific Precision Medicine Service
Key Customers	Healthcare and medical R&D institutions Pharmaceutical corporations Hospitals and cancer-specific clinics



### Products and services

- Automated high-throughput organoid screening platform development and manufacturing
- **OncoSensi®**, a patient-specific anti-cancer drug sensitivity testing service (implemented in over 30 university hospitals in Korea)
- **CRO & Screening services** for drug efficacy and toxicity evaluation using PDOs
- **Organoid library**: a patient-derived organoid library integrated with both genetic biomarker and phenotypic drug-response data, including ovarian cancer organoid 20ea, colorectal cancer organoid 36ea, Lung cancer organoid 39ea.

### Contact

CEO Bo Sung Ku

#### Business Contact

Taeheum Baek  
[bth@mbdbiotech.com]

### Certifications

- CE Marking (EU)
- FDA (USA)
- ISO-13485:2016
- ISO/TC 229-TR 22455
- CLIA Lab certification

### Business Info

Founded

2015

Employees (2025)

50

Target Markets

EMEA, USA, East Asia

Sales (2025)

USD 350K

Total Funding

USD 27M

Stage

Growth

Investment Round

Series C Bridge, Pre-IPO (upcoming Q2 2026)

### Media

Website

[https://www.mbdbiotech.com/index\\_en.php](https://www.mbdbiotech.com/index_en.php)

LinkedIn / SNS

<https://www.linkedin.com/company/mbd-medical-bio-decision>